Authors
Latest:
Dr. Leleu on the Future of Later-Line Therapy in Multiple MyelomaXavier Leleu, MD, PhD, discusses how the declining prognosis of patients with multiple myeloma correlates with line of therapy and time after diagnosis, highlighting an unmet need for more effective later-line therapies in this population.
Latest:
Dr. Weksler on Addressing Disparities in Lung Cancer Care DeliveryBenny Weksler, MD, MBA, FACS, FACCP, discusses efforts being made at Allegheny Health Network Cancer Institute to address disparities in the delivery of care and its impact on the screening and treatment of lung cancer.
Latest:
Gita Suneja Named Senior Director of Programs to Enhance DiversityGita Suneja, MD, MS, has been named the senior director of Programs to Enhance Diversity at Huntsman Cancer Institute.
Latest:
Pembrolizumab/Chemo With or Without Bevacizumab Has Potential as New SOC in Metastatic Cervical CancerNicoletta Colombo, MD, PhD, discusses the practice-changing data to emerge from KEYNOTE-826 and the next steps for the pembrolizumab plus chemotherapy with or without bevacizumab regimen in patients with cervical cancer.
Latest:
Dr. Zakhour on the Utilization of Tisotumab Vedotin in Cervical CancerMae Zakhour, MD, discusses the utilization of tisotumab vedotin-tftv in cervical cancer.
Latest:
Dr Islam on the Limited Use of Ibrutinib in CLLPrioty Islam, MD, MSc, discusses the current status of the first-generation BTK inhibitor ibrutinib following the FDA approvals of next-generation BTK inhibitors in patients with chronic lymphocytic leukemia and expands on the few instances in the clinic where she may lean toward treatment with ibrutinib instead of the next-generation BTK inhibitors zanubrutinib or acalabrutinib.
Latest:
Dr. Shaukat on the Benefit of Diverse Enrollment in Clinical Trials in CRCAasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.
Latest:
US Biosimilar Portfolio Hits 10-Year Mark in Growth ModeSince the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.
Latest:
Dr Montes de Oca on the Use of Cryocompression to Reduce Peripheral Neuropathy in Gynecologic CancersMary Katherine Montes de Oca, MD, discusses the use of cryocompression to reduce chemotherapy-induced peripheral neuropathy in gynecologic cancers.
Latest:
Findings Suggest Cholesterol Plays a Surprising Role in Pancreatic CancerAlthough a majority of pancreatic cancer cells are highly dependent on endogenous biosynthesis of cholesterol, new research from investigators at Fox Chase Cancer Center has demonstrated that some more aggressive pancreatic cancers are completely independent of this process.
Latest:
The Future of Molecular Testing in NSCLCThe panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.
Latest:
Dr. Toppmeyer on Sequencing Therapy in HER2+ Breast CancerDeborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.
Latest:
Dr. Danilov on the Next Steps for Researching Noncovalent BTK Inhibitors in MCLAlexey V. Danilov, MD, PhD, discusses the next steps for researching noncovalent BTK inhibitors in mantle cell lymphoma.
Latest:
Dr González-González on DDR Pathway Inhibition in HER2-low TNBC Breast Cancer ModelsAdrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.
Latest:
Rapid Readouts: A Global Study of Advanced Dosimetry in the Treatment of HCC With Y 90 Glass MicrospheresRiad Salem, MD, presents slides supporting global real-world data confirming a significant association between tumor-absorbed dose, objective response between tumor-absorbed dose and overall survival in patients with hepatocellular carcinoma (HCC) treated with yttrium-90 glass microspheres.
Latest:
Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLCMichael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.
Latest:
Dr Lang on Ocular Toxicities Following ADC Treatment in Ovarian CancerSusan Marie Lang, MD, discusses the incidence of ocular toxicity following treatment with mirvetuximab soravtansine in ovarian cancer.
Latest:
Struggling With COVID-19 on the Cancer FloorFor the population of hospitalized patients with cancer, many of whom who have not contracted the disease, COVID-19 has real, immediate consequences; the pandemic has radically altered their end-of-life care.
Latest:
Dr. Silbermann on the CASTOR Trial in Relapsed/Refractory MyelomaRebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.
Latest:
Dr. Majem on the Safety Profile of Osimertinib in EGFR+ NSCLCMargarita Majem, MD, PhD, discusses the safety profile of osimertinib in patients with EGFR-mutated non–small cell lung cancer.
Latest:
Dr. Maris on Key Results From the OUTREACH Trial of Liso-cel in DLBCLMichael Maris, MD, discusses key efficacy and safety data from the phase 2 OUTREACH trial in diffuse large B-cell lymphoma.
Latest:
Dr. Osipov on the Role of Combination Immunotherapy Across Multiple Tumor TypesArsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.
Latest:
Treatment Advances in HR+ Breast CancerA panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.
Latest:
Dr. Cavnar on the Use of Hepatic Artery Infusion Pumps in CRC With Liver MetastasesMichael J. Cavnar, MD, discusses the use of hepatic artery infusion pumps in patients with colorectal cancer with liver metastases.
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two DecadesPostoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Latest:
Career Options for Graduating Oncology Fellows at the NIH and FDAPeter J. DeMaria, MD and Jennifer J. Gao, MD shed light on how graduating fellows seeking a rewarding and intellectually challenging career on the frontier of cancer drug development could be well served to consider a position of federal service at the NIH or FDA.
Latest:
Dr Ademuyiwa on the Sequencing of First-line CDK4/6 Inhibitors in HR+/HER2– Breast CancerFoluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor (HR)–positive, HER2-negative breast cancer based on updated efficacy and safety data.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
